Sylphar Receives Private Equity Investment from Vendis Capital

Sylphar, a Deurle (Belgium)-based OTC company with a portfolio of brands in the oral beauty, oral therapy and medicated skincare market segments, received a private equity investment of undisclosed amount.

Backers included Vendis Capital, founder Robin List and his management team.

The company intends to use the funds to further develop its offering and expand operations.

Started by Robin List in 2008 as a spin-off from a publicly listed dental company and supported by Dutch private equity fund Concordia, Sylphar offers teeth whitening products under the brand iWhite, an innovative range of solutions for specific skin conditions under the Remescar brand, and oral therapeutics under the Herpatch (cold sores and ulcers) and Shur (bad breath) brands.

Present in more than 50 countries worldwide, the company focuses on developing and marketing innovative products that are brought to the market through local distribution partners.



Join the discussion